Nephrogenic systemic fibrosis

Jeffrey C Weinreb; Phillip H Kuo

doi:10.1016/j.mric.2009.01.003

Nephrogenic systemic fibrosis

Magn Reson Imaging Clin N Am. 2009 Feb;17(1):159-67. doi: 10.1016/j.mric.2009.01.003.

Authors

Jeffrey C Weinreb¹, Phillip H Kuo

Affiliation

¹ Department of Diagnostic Radiology, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208042, New Haven, CT 06520-5913, USA. jeffrey.weinreb@yale.edu

PMID: 19364606
DOI: 10.1016/j.mric.2009.01.003

Abstract

There seems to be an association between exposure to intravenous gadolinium-based contrast agents (GBCAs) and nephrogenic systemic fibrosis (NSF), a debilitating and sometimes fatal disease. This article addresses the relationship between GBCAs and NSF and answers some common questions. The policy deployed at Yale-New Haven Hospital for prevention of NSF and screening for patients at risk is delineated and discussed along with recommendations by the Food and Drug Administration.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Contrast Media / adverse effects*
Gadolinium / adverse effects*
Glomerular Filtration Rate
Humans
Magnetic Resonance Imaging / methods*
Nephrogenic Fibrosing Dermopathy / chemically induced*
Nephrogenic Fibrosing Dermopathy / prevention & control*
Risk Factors

Substances

Contrast Media
Gadolinium